We Think That There Are Issues Underlying Biosino Bio-Technology and Science Incorporation's (HKG:8247) Earnings

By
Simply Wall St
Published
August 19, 2021
SEHK:8247
Source: Shutterstock

Despite posting some strong earnings, the market for Biosino Bio-Technology and Science Incorporation's (HKG:8247) stock hasn't moved much. Our analysis suggests that shareholders have noticed something concerning in the numbers.

See our latest analysis for Biosino Bio-Technology and Science Incorporation

earnings-and-revenue-history
SEHK:8247 Earnings and Revenue History August 19th 2021

How Do Unusual Items Influence Profit?

To properly understand Biosino Bio-Technology and Science Incorporation's profit results, we need to consider the CN¥9.2m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. Biosino Bio-Technology and Science Incorporation had a rather significant contribution from unusual items relative to its profit to June 2021. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Biosino Bio-Technology and Science Incorporation.

Our Take On Biosino Bio-Technology and Science Incorporation's Profit Performance

As previously mentioned, Biosino Bio-Technology and Science Incorporation's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. For this reason, we think that Biosino Bio-Technology and Science Incorporation's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. While conducting our analysis, we found that Biosino Bio-Technology and Science Incorporation has 4 warning signs and it would be unwise to ignore them.

This note has only looked at a single factor that sheds light on the nature of Biosino Bio-Technology and Science Incorporation's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

If you're looking for stocks to buy, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted


Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.